

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: [www.ejcancer.com](http://www.ejcancer.com)

## Corrigendum

## Corrigendum to “Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma” [Eur J Cancer 126 (2020) 93–103]

Didier Decaudin <sup>a,b,1</sup>, Estelle Frisch Dit Leitz <sup>c,1</sup>, Fariba Nemati <sup>a,1</sup>, Malcy Tarin <sup>c</sup>, Adnan Naguez <sup>a</sup>, Mohamed Zerara <sup>a</sup>, Benjamin Marande <sup>c</sup>, Raquel Vivet-Noguer <sup>c</sup>, Ensar Halilovic <sup>d</sup>, Claire Fabre <sup>d</sup>, Aart Jochemsen <sup>e</sup>, Sergio Roman-Roman <sup>c</sup>, Samar Alsafadi <sup>c,\*</sup>

<sup>a</sup> *Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France*

<sup>b</sup> *Department of Medical Oncology, Institut Curie, Paris, France*

<sup>c</sup> *Uveal Melanoma Translational Group, Department of Translational Research, Institut Curie, PSL Research University, Paris, France*

<sup>d</sup> *Novartis Institutes for Biomedical Research, Cambridge, MA, USA*

<sup>e</sup> *Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands*

The authors regret that the acknowledgements section of the published paper was incomplete and should include the following statement:

Raquel Vivet-Noguer was supported by the Institut Curie 3-i PhD Program under Marie Skłodowska-Curie Grant Agreement No 666003.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.ejca.2019.12.012>.

\* *Corresponding author:*

*E-mail addresses:* [samar.alsafadi@curie.fr](mailto:samar.alsafadi@curie.fr), [samaralsafadi@yahoo.com](mailto:samaralsafadi@yahoo.com) (S. Alsafadi).

<sup>1</sup> Joint first co-author.

<https://doi.org/10.1016/j.ejca.2023.02.004>

0959-8049/© 2023 The Author(s). Published by Elsevier Ltd. All rights reserved.